PATIROMER

Generic	Brand	HICL	GCN	Exception/Other
PATIROMER CALCIUM SORBITEX	VELTASSA	42767		

GUIDELINES FOR USE

1. Is the patient being treated for hyperkalemia **AND** meet the following criterion?
   - Therapy is prescribed by or in consultation with a nephrologist or cardiologist

   If yes, continue to #2.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

2. Does the patient meet **ONE** of the following criteria?
   - The requested drug is being used as an emergency treatment for life-threatening hyperkalemia
   - The patient is currently receiving dialysis

   If yes, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.
   If no, continue to #3.

3. Has the patient attempted **ONE** of the following approaches in an effort to reduce the modifiable risks for hyperkalemia?
   - Limit to taking no more than one of the following drugs at any given time:
     - Angiotensin converting enzyme inhibitor (ACE-I)
     - Angiotensin receptor blocker (ARB)
   - Consideration of dose reduction of renin-angiotensin-aldosterone system (RAAS) inhibitors (e.g., ACE-I's, ARB's, aldosterone antagonists)

   If yes, continue to #4.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

4. Does the patient have an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m^2 **AND** meet the following criterion?
   - The patient has tried loop diuretics (e.g., bumetanide, ethacrynic acid, furosemide, torsemide) for the treatment of hyperkalemia

   If yes, continue to #6.
   If no, continue to #5.

CONTINUED ON NEXT PAGE

PATIROMER

GUIDELINES FOR USE (CONTINUED)

5. Does the patient have an estimated glomerular filtration rate (eGFR) of 30 mL/min/1.73 m^2 or above and have tried **ONE** of the following for the treatment of hyperkalemia?
   - The patient has tried loop diuretic (e.g., bumetanide, ethacrynic acid, furosemide, torsemide)
   - The patient has tried thiazide diuretic (e.g., chlorthalidone, hydrochlorothiazide, metolazone)

   If yes, continue to #6.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

6. Has the patient had a previous trial of Lokelma (sodium zirconium cyclosilicate)?

   If yes, **approve for 12 months by HICL with a quantity limit of #30 packets per 30 days.**
   If no, do not approve.
   DENIAL TEXT: The guideline named **PATIROMER (Veltassa)** requires a diagnosis of hyperkalemia. In addition, the following criteria must also be met:
   - Therapy is prescribed by or in consultation with a nephrologist or cardiologist
   - The requested drug is NOT being used as an emergency treatment for life-threatening hyperkalemia
   - The requested drug will NOT be approved for a patient currently receiving dialysis
   - The patient has attempted **ONE** of the following approaches in an effort to reduce the modifiable risks for hyperkalemia:
     - Limit to taking no more than one of the following drugs at any given time (Angiotensin converting enzyme inhibitor [ACE-I], Angiotensin receptor blocker [ARB])
     - Consideration of dose reduction of renin-angiotensin-aldosterone system (RAAS) inhibitors (e.g., ACE-I's, ARB's, aldosterone antagonists)
   - The patient has had a previous trial of Lokelma (sodium zirconium cyclosilicate)
   - If estimated glomerular filtration rate (eGFR) is below 30 mL/min/1.73 m(2): the patient has tried to treat hyperkalemia with loop diuretics (e.g., bumetanide, ethacrynic acid, furosemide, torsemide)
   - If estimated glomerular filtration rate (eGFR) is 30 mL/min/1.73 m(2) or above: the patient has tried to treat hyperkalemia with a loop diuretic (e.g., bumetanide, ethacrynic acid, furosemide, torsemide), OR thiazide diuretic (e.g., chlorthalidone, hydrochlorothiazide, metolazone)

CONTINUED ON NEXT PAGE

PATIROMER

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Review for PATIROMER

REFERENCES

- Veltassa [Prescribing Information]. Relypsa, Inc.: Redwood City, CA; October 2015.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A
Commercial Effective: 04/01/19
Created: 2/16
Client Approval: 03/19
P&T Approval: 01/19